ACTIS LAW GROUP is investigating a class action lawsuit against Lemme Inc., co-owned by Kourtney Kardashian, for allegedly falsely and misleadingly marketing and advertising its dietary supplements, Lemme GLP-1 Daily capsules, as being capable of and effective in treating obesity, aiding in weight loss, and reducing other weight-related health risks.

GLP-1, or “glucagon-like peptide-1”, is a hormone that produced naturally in the human body after a meal that helps regulate blood sugar, slow digestion, and manage hunger/cravings.

GLP-1 receptor agonists, such as semaglutide in Ozempic and Wegovy, mimic GLP-1 and are approved for weight management and for type 2 diabetes.

The GLP-1 Daily capsules are co-owned by Kourtney Kardashian Barker’s wellness brand “Lemme”, which claims to boost GLP-1 levels, reduce hunger, and promote healthy weight loss, but doctors are skeptical about its effectiveness, as doesn’t contain the same active ingredient as FDA-approved GLP-1 drugs such as Ozempic and Wegovy.

Instead, Lemme GLP-1 Daily capsules contain the “active ingredients” of only orange extract, saffron extract, and a lemon extract (Morosil Red Orange Fruit Extract, Supresa Saffron Extract, and Eriomin Lemon Fruit Extract).

Among other advertising, there is a product web page with the headline: “How GLP-1 your ‘un-hunger’ hormone works.” It goes on to say: “GLP-1 helps you feel full and supports glucose metabolism. But factors like age, lifestyle, and diet can affect your body’s ability to produce GLP-1. That’s where we come in.”

The idea behind the Kardashian GLP-1 Daily capsules is to capitalize on the GLP-1 craze and dupe Canadians into buying them instead of other actually effective medications.

The Defendant falsely claims that supplementing naturally occurring GLP-1 with Lemme GLP-1 Daily reduces hunger and leads to weight loss. Even if the studies on which the defendant relies were not flawed (among other things, they are based on sample sizes that are far too small to draw valid statistical conclusions), there is no clinical evidence that increasing the amount of GLP-1 in the body by 17 percent has any effect on “un-hunger” or on blood pressure, body weight, BMI, mass, fat and hip-waist ratio.

The class consists of all Canadians who have purchased Lemme GLP-1 Daily Capsule Products.

If you or someone you know has bought one or more Lemme GLP-1 Daily Capsules and you wish to obtain more information on potential compensation or to be kept advised of the status of the Class Action litigation or any resulting compensation resulting from the Class Action Lawsuit, please provide your contact information to our law firm using the below form.